|
1
|
Zhao T, Mao G, Zhang M, Zou Y, Feng W, Gu
X, Zhu Y, Mao R, Yang L and Wu X: Enhanced antitumor and reduced
toxicity effect of Schisanreae polysaccharide in 5-Fu treated
Heps-bearing mice. Int J Biol Macromol. 63:114–118. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cao Z, Liao L, Chen X, Lan L, Hu H, Liu Z,
Chen L, Huang S and Du J: Enhancement of antitumor activity of
low-dose 5-fluorouracil by combination with Fuzheng-Yiliu granules
in hepatoma 22 tumor-bearing mice. Integr Cancer Ther. 12:174–181.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Simonetti RG, Liberati A, Angiolini C and
Pagliaro L: Treatment of hepatocellular carcinoma: A systematic
review of randomized controlled trials. Ann Oncol. 8:117–136. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng MR, Li Q, Wan T, He B, Han J, Chen
HX, Yang FX, Wang W, Xu HZ, Ye T and Zha BB: Galactosylated
chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer
growth and its side effects. World J Gastroenterol. 18:6076–6087.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boucher E, Corbinais S, Brissot P,
Boudjema K and Raoul JL: Treatment of hepatocellular carcinoma
(HCC) with systemic chemotherapy combining epirubicin, cisplatinum
and infusional 5-fluorouracil (ECF regimen). Cancer Chemother
Pharmacol. 50:305–308. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fan Y, Lu Y, Wang D, Liu J, Song X, Zhang
W, Zhao X, Nguyen TL and Hu Y: Effect of epimedium
polysaccharide-propolis flavone immunopotentiator on
immunosuppression induced by cyclophosphamide in chickens. Cell
Immunol. 281:37–43. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liao HF, Chen YJ and Yang YC: A novel
polysaccharide of black soybean promotes myelopoiesis and
reconstitutes bone marrow after 5-flurouracil- and
irradiation-induced myelosuppression. Life Sci. 77:400–413. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang J, Wang Y, Liu X, Yuan Y and Yue T:
Free radical scavenging and immunomodulatory activities of
Ganoderma lucidum polysaccharides derivatives. Carbohydr Polym.
91:33–38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hou S, Kou G, Fan X, Wang H, Qian W, Zhang
D, Li B, Dai J, Zhao J, Ma J, et al: Eradication of hepatoma and
colon cancer in mice with Flt3L gene therapy in combination with
5-FU. Cancer Immunol Immunother. 56:1605–1613. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park SH, Lee Y, Han SH, Kwon SY, Kwon OS,
Kim SS, Kim JH, Park YH, Lee JN, Bang SM, et al: Systemic
chemotherapy with doxorubicin, cisplatin and capecitabine for
metastatic hepatocellular carcinoma. BMC Cancer. 6:32006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Z, Wu B, Zhang X, Xu M, Chang H, Lu X
and Ren X: Purification of a polysaccharide from Boschniakia
rossica and its synergistic antitumor effect combined with
5-Fluorouracil. Carbohydr Polym. 89:31–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Crabtree GR: Generic signals and specific
outcomes: Signaling through Ca2+, calcineurin, and NF-AT. Cell.
96:611–614. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Manalan AS and Klee CB: Activation of
calcineurin by limited proteolysis. Proc Natl Acad Sci USA. 80:pp.
4291–4295. 1983; View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu X, Nguyen BC, Dziunycz P, Chang S,
Brooks Y, Lefort K, Hofbauer GF and Dotto GP: Opposing roles for
calcineurin and ATF3 in squamous skin cancer. Nature. 465:368–372.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Euvrard S, Kanitakis J and Claudy A: Skin
cancers after organ transplantation. N Engl J Med. 348:1681–1691.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Heit JJ, Apelqvist AA, Gu X, Winslow MM,
Neilson JR, Crabtree GR and Kim SK: Calcineurin/NFAT signalling
regulates pancreatic beta-cell growth and function. Nature.
443:345–349. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Neilson JR, Winslow MM, Hur EM and
Crabtree GR: Calcineurin B1 is essential for positive but not
negative selection during thymocyte development. Immunity.
20:255–266. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Januschke J, Reina J, Llamazares S,
Bertran T, Rossi F, Roig J and Gonzalez C: Centrobin controls
mother-daughter centriole asymmetry in Drosophila neuroblasts. Nat
Cell Biol. 15:241–248. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saeki M, Irie Y, Ni L, Itsuki Y, Terao Y,
Kawabata S and Kamisaki Y: Calcineurin potentiates the activation
of procaspase-3 by accelerating its proteolytic maturation. J Biol
Chem. 282:11786–11794. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei Q, Lian ML, Jing FZ, Zhang N, Yan MS,
Chen Y and Gao QS: Studies of calcineurin B subunit from genetic
engineering for use in medicine. Drug Dev Res. 56:40–43. 2002.
View Article : Google Scholar
|
|
22
|
Li J, Guo J, Su Z, Hu M, Liu W and Wei Q:
Calcineurin subunit B activates dendritic cells and acts as a
cancer vaccine adjuvant. Int Immunol. 23:327–334. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu M, Su Z, Yin Y, Li J and Wei Q:
Calcineurin B subunit triggers innate immunity and acts as a novel
Engerix-B HBV vaccine adjuvant. Vaccine. 30:4719–4727. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su Z, Xin S, Xu L, Cheng J, Guo J, Li L
and Wei Q: The calcineurin B subunit induces TNF-related
apoptosis-inducing ligand (TRAIL) expression via CD11b-NF-κB
pathway in RAW264. 7 macrophages. Biochem Biophys Res Commun.
417:777–783. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu L, Su Z, Xin S, Cheng J, Li J, Xu L
and Wei Q: The calcineurin B subunit (CnB) is a new ligand of
integrin αM that mediates CnB-induced Apo2L/TRAIL expression in
macrophages. J Immunol. 188:238–247. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Su Z, Yang R, Zhang W, Xu L, Zhong Y, Yin
Y, Cen J, DeWitt JP and Wei Q: The synergistic interaction between
the calcineurin B subunit and IFN-γ enhances macrophage antitumor
activity. Cell Death Dis. 6:e17402015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Su Z, Xin S, Li J, Guo J, Long X, Cheng J
and Wei Q: A new function for the calcineurin b subunit:
Antiplatelet aggregation and anticoagulation. IUBMB Life.
63:1037–1044. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Li L, Huang Y and Wei Q:
Calcineurin subunit B upregulates β-interferon production by
phosphorylation of interferon regulatory factor 3 via Toll-like
receptor 4. Cancer Sci. 103:515–521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jia L, Xu B, Guo W, Ge ZM, Li RT and Cui
JR: Enhanced antitumor effect of TM208 in combination with 5
fluorouracil in H22 transplanted mice. J Chine Pharmace Sci.
20:615–626. 2011.
|
|
30
|
Rolny C, Mazzone M, Tugues S, Laoui D,
Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, et
al: HRG inhibits tumor growth and metastasis by inducing macrophage
polarization and vessel normalization through downregulation of
PlGF. Cancer Cell. 19:31–44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Antoon JW, White MD, Slaughter EM, Driver
JL, Khalili HS, Elliott S, Smith CD, Burw ME and Beckman BS:
Targeting NFκB mediated breast cancer chemoresistance through
selective inhibition of sphingosine kinase-2. Cancer Biol Ther.
11:678–689. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hosaka N, Ichikawa Y, Ishikawa T,
Nagashima Y, Kunisaki C, Takahashi M, Moriwaki Y, Akiyama H,
Yamaguchi S, Ota M, et al: Correlation of immunohistochemical p53
labeling index with inhibition rate in chemosensitivity test in
gastric and colon cancer. Anticancer Res. 21:229–235. 2000.
|
|
33
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
El-Sayyad HI, Ismail MF, Shalaby F,
Abou-El-Magd R, Gaur RL, Fernando A, Raj MH and Ouhtit A:
Histopathological effects of cisplatin, doxorubicin and
5-flurouracil (5-FU) on the liver of male albino rats. Int J Biol
Sci. 5:466–473. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schmoll HJ and Arnold D: Update on
capecitabine in colorectal cancer. Oncologist. 11:1003–1009. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hejna M and Zielinski CC: Nonsurgical
management of gallbladder cancer: Cytotoxic treatment and
radiotherapy. Expert Rev Anticancer Ther. 1:291–300. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Knox JJ, Hedley D, Oza A, Siu LL, Pond GR
and Moore MJ: Gemcitabine concurrent with continuous infusional
5-fluorouracil in advanced biliary cancers: A review of the
Princess Margaret Hospital experience. Ann Oncol. 15:770–774. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Todoroki T: Chemotherapy for gallbladder
carcinoma-a surgeon's perspective. Hepatogastroenterology.
47:948–955. 2000.PubMed/NCBI
|
|
39
|
Harrop R, Drury N, Shingler W, Chikoti P,
Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven
N and Hawkins RE: Vaccination of colorectal cancer patients with
TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and
irinotecan) is safe and induces potent immune responses. Cancer
Immunol Immunother. 57:977–986. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kobayashi K, Tsuji A, Morita S, Horimi T,
Shirasaka T and Kanematsu T: A phase II study of LFP therapy (5-FU
(5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive
(Cisplatin) CDDP) in advanced biliary tract carcinoma. BMC Cancer.
6:1212006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nowak AK, Chow PK and Findlay M: Systemic
therapy for advanced hepatocellular carcinoma: A review. Eur J
Cancer. 40:1474–1484. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wei Q and Lee EY: Expression and
reconstitution of calcineurin A and B subunits. Biochem Mol Biol
Int. 41:169–177. 1997.PubMed/NCBI
|
|
43
|
Shoemaker M, Hamilton B, Dairkee SH, Cohen
I and Campbell MJ: In vitro anticancer activity of twelve Chinese
medicinal herbs. Phytother Res. 19:649–651. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tang W, Hemm I and Bertram B: Recent
development of antitumor agents from Chinese herbal medicines; part
I. Low molecular compounds. Planta Med. 69:97–108. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lazarou J, Pomeranz BH and Corey PN:
Incidence of adverse drug reactions in hospitalized patients: A
meta-analysis of prospective studies. Jama. 279:1200–1205. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
van Kuilenburg AB, Meinsma R, Zonnenberg
BA, Zoetekouw L, Baas F, Matsuda K, Tamaki N and van Gennip AH:
Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.
Clin Cancer Res. 9:4363–4367. 2003.PubMed/NCBI
|
|
47
|
Kornek G, Raderer M, Schüll B, Fiebiger W,
Gedlicka C, Lenauer A, Depisch D, Schneeweiss B, Lang F and
Scheithauer W: Effective combination chemotherapy with paclitaxel
and cisplatin with or without human granulocyte colony-stimulating
factor and/or erythropoietin in patients with advanced gastric
cancer. Br J Cancer. 86:1858–1863. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liljenfeldt L, Gkirtzimanaki K, Vyrla D,
Svensson E, Loskog AS and Eliopoulos AG: Enhanced therapeutic
anti-tumor immunity induced by co-administration of 5-fluorouracil
and adenovirus expressing CD40 ligand. Cancer Immunol Immunother.
63:273–282. 2014. View Article : Google Scholar : PubMed/NCBI
|
